Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2020 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: HSK42360
Page 1
Pan-Cancer Efficacy of Vemurafenib in BRAF (V600)-Mutant Non-Melanoma Cancers.
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, Hyman DM. Subbiah V, et al. Cancer Discov. 2020 May;10(5):657-663. doi: 10.1158/2159-8290.CD-19-1265. Epub 2020 Feb 6. Cancer Discov. 2020. PMID: 32029534 Free PMC article.
BRAF (V600) mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers. ...To address this, we conducted a multicohort "basket" study of the BRAF inhibitor vemurafenib in non-melanoma BRAF …
BRAF (V600) mutations occur in a wide range of tumor types, and RAF inhibition has become standard in several of these cancers …
BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.
Preusser M, Bienkowski M, Birner P. Preusser M, et al. Expert Opin Investig Drugs. 2016;25(1):7-14. doi: 10.1517/13543784.2016.1110143. Epub 2015 Nov 4. Expert Opin Investig Drugs. 2016. PMID: 26536389 Review.
Small kinase inhibitors of v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) have shown considerable antineoplastic activity in some tumor types harboring activating BRAF-V600 mutations (e.g., melanoma) and promising data are emerging on BRAF inhibit …
Small kinase inhibitors of v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) have shown considerable antineoplastic activity in some t …
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.
Robinson GW, Orr BA, Gajjar A. Robinson GW, et al. BMC Cancer. 2014 Apr 12;14:258. doi: 10.1186/1471-2407-14-258. BMC Cancer. 2014. PMID: 24725538 Free PMC article.
Molecular analysis of the primary tumor revealed a BRAF V600E mutation and the patient was placed on the BRAF inhibitor vemurafenib. A complete response was observed after 4 months of therapy and remains sustained at 6 months. CONCLUSION: This is the first report of …
Molecular analysis of the primary tumor revealed a BRAF V600E mutation and the patient was placed on the BRAF inhibitor vemura …
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Nelson MV, Kim A, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Nelson MV, et al. Oncologist. 2024 Aug 5;29(8):723-e1093. doi: 10.1093/oncolo/oyae119. Oncologist. 2024. PMID: 38873934 Free PMC article. Clinical Trial.
BACKGROUND: This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory solid tumors harboring BRAF V600 mutations. ...Prima …
BACKGROUND: This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRA …
BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities.
Rizzo D, Ruggiero A, Amato M, Maurizi P, Riccardi R. Rizzo D, et al. Expert Opin Drug Metab Toxicol. 2016 Dec;12(12):1397-1405. doi: 10.1080/17425255.2016.1214710. Epub 2016 Aug 5. Expert Opin Drug Metab Toxicol. 2016. PMID: 27494648 Review.
Development of selective inhibitors of BRAF has improved the survival of patients with melanoma and offers potential new therapeutic strategy in children with BRAF-mutant glioma. Areas covered: Mechanisms of resistance to BRAF inhibitors have recently been described as due …
Development of selective inhibitors of BRAF has improved the survival of patients with melanoma and offers potential new therapeutic strateg …